Intended for healthcare professionals


French medicine regulator bans two cannabinoid derivatives after reported side effects

BMJ 2024; 385 doi: (Published 06 June 2024) Cite this as: BMJ 2024;385:q1249
  1. Barbara Casassus
  1. Paris

France’s medicine regulator, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), has banned the production, sale, and use of two new families of cannabinoid derivatives because of reported serious side effects and potential addiction.

The ban, which took effect on 3 June, concerns both semi-synthetic (chemically modified natural) substances and synthetic products that are sold online and in shops. The semi-synthetic molecules include H4-CBD and H2-CBD, as well as certain derivatives with a chemical core called benzo[c]chromene.

Pure cannabidiol (CBD) and cannabinol (CBN) remain authorised, and according to an updated ANSM announcement on 4 June so do four benzo[c]chromene based products.

The synthetic products, based on …

View Full Text

Log in

Log in through your institution


* For online subscription